# A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

> **NCT01187407** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1480 (actual)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** LY2216684
- **DRUG:** Placebo
- **DRUG:** SSRI

## Key facts

- **NCT ID:** NCT01187407
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 1480 (ACTUAL)
- **Last updated:** 2018-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01187407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01187407, "A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01187407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*